mRNA Delivery to Skin

In addition to being the largest and most accessible organ of the body, the skin contains large numbers of highly active cells that have a high capacity for protein synthesis. These characteristics make the skin an ideal platform for expressing therapeutic proteins, both locally, for the treatment of dermatological conditions, and systemically, for the treatment of a wide range of diseases and conditions.

Our scientists developed a method for expressing therapeutic proteins, including circulating proteins, by administering ultra-low doses of mRNA to the skin.

mRNA Delivery to Skin is protected by a pending U.S. patent (with additional patents pending in other countries).

• Express proteins locally for the treatment of dermatologic conditions (e.g., elastin for the rare genetic disease cutis laxa and aesthetic applications)
• Express proteins systemically for the treatment of a wide range of diseases and conditions (e.g., BMP7 for diabetic nephropathy)
• Deliver the therapy directly to the patient’s skin – avoid ex vivo cell manipulation

• Combine with Factor’s Chromatin Context-Sensitive Gene-Editing Endonuclease for high-specificity in vivo gene editing
• Combine with Factor’s ToRNAdo™ Nucleic-Acid Delivery System for high efficiency in vivo delivery – proven delivery to human skin in vivo